JD HEALTH
06618
NTES-S
09999
ALI HEALTH
00241
4
BEKE-W
02423
5
BILIBILI-W
09626
(FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -12.77%1.69B | -26.82%871.96M | 23.41%1.94B | 29.61%1.19B | -9.23%1.57B | -23.73%919.26M | 18.11%1.73B | -0.60%1.21B | -45.33%1.46B | -35.59%1.21B |
Operating income | -12.77%1.69B | -26.82%871.96M | 23.41%1.94B | 29.61%1.19B | -9.23%1.57B | -23.73%919.26M | 18.11%1.73B | -0.60%1.21B | -45.33%1.46B | -35.59%1.21B |
Cost of sales | 12.68%-1.64B | 25.43%-855.25M | -23.56%-1.88B | -30.53%-1.15B | 5.58%-1.52B | 24.14%-878.62M | -23.00%-1.61B | -5.43%-1.16B | 46.65%-1.31B | 34.40%-1.1B |
Operating expenses | 12.68%-1.64B | 25.43%-855.25M | -23.56%-1.88B | -30.53%-1.15B | 5.58%-1.52B | 24.14%-878.62M | -23.00%-1.61B | -5.43%-1.16B | 46.65%-1.31B | 34.40%-1.1B |
Gross profit | -15.53%49.71M | -62.54%16.71M | 18.70%58.85M | 9.76%44.6M | -58.46%49.58M | -13.76%40.64M | -23.13%119.34M | -58.66%47.13M | -30.85%155.25M | -45.17%114.01M |
Administrative expenses | 7.17%-136.31M | -1.79%-73.22M | 17.11%-146.84M | 25.17%-71.93M | 18.91%-177.15M | 19.02%-96.13M | 39.84%-218.44M | -2.25%-118.71M | -7.04%-363.13M | 7.81%-116.1M |
Impairment and provision | -446.46%-37.14M | -92.43%1.74M | -70.66%10.72M | 55.55%22.97M | 112.31%36.53M | -57.00%14.77M | 91.76%-296.86M | 24.34%34.35M | -62,770.27%-3.6B | -32.85%27.62M |
-Other impairment is provision | -446.46%-37.14M | -92.43%1.74M | -70.66%10.72M | 55.55%22.97M | 112.31%36.53M | -57.00%14.77M | 91.76%-296.86M | 24.34%34.35M | -62,770.27%-3.6B | -32.85%27.62M |
Operating interest expense | ---- | ---- | ---- | ---- | ---- | 18.64%-52.77M | 19.25%-157.84M | 38.91%-64.86M | 19.95%-195.46M | 22.16%-106.17M |
Special items of operating profit | -0.33%48.39M | 137.08%3.03M | 458.41%48.55M | 65.16%-8.17M | 109.60%8.69M | -1,676.06%-23.44M | 58.78%-90.54M | -106.88%-1.32M | -253.69%-219.63M | 10.45%19.19M |
Operating profit | -162.34%-75.35M | -313.27%-51.74M | 65.12%-28.72M | 89.29%-12.52M | 87.22%-82.35M | -13.07%-116.94M | 84.75%-644.35M | -68.30%-103.42M | -1,909.95%-4.23B | -1,601.27%-61.45M |
Financing cost | 36.30%-110.66M | 16.34%-64.17M | -29.71%-173.74M | ---76.7M | ---133.94M | ---- | ---- | ---- | ---- | ---- |
Share of profits of associates | 0.02%302.31M | 24.97%169.52M | 24.43%302.25M | -1.07%135.65M | -35.10%242.9M | -6.48%137.11M | 16.81%374.29M | 21.89%146.62M | 4.81%320.43M | -24.49%120.29M |
Share of profit from joint venture company | -118.18%-14K | 26.88%203K | 101.79%77K | 126.67%160K | ---4.3M | 31.66%-600K | ---- | 63.70%-878K | -847.11%-11.77M | -121.93%-2.42M |
Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --31.02M |
Earning before tax | 16.43%116.27M | 15.51%53.82M | 347.42%99.87M | 137.98%46.59M | 108.27%22.32M | -53.75%19.58M | 93.11%-270.06M | -51.60%42.33M | -4,136.80%-3.92B | -46.12%87.45M |
Tax | -318.11%-31.33M | -249.97%-12.27M | 30.21%-7.49M | -176.28%-3.51M | -26.33%-10.74M | 61.20%-1.27M | -107.67%-8.5M | 45.31%-3.27M | 578.36%110.83M | -172.61%-5.98M |
After-tax profit from continuing operations | -8.04%84.95M | -3.57%41.55M | 697.44%92.38M | 135.33%43.08M | 104.16%11.58M | -53.12%18.31M | 92.68%-278.56M | -52.06%39.06M | -5,252.84%-3.81B | -49.12%81.46M |
Earning after tax | -8.04%84.95M | -3.57%41.55M | 697.44%92.38M | 135.33%43.08M | 104.16%11.58M | -53.12%18.31M | 92.68%-278.56M | -52.06%39.06M | -5,252.84%-3.81B | -49.12%81.46M |
Minority profit | -101.18%-121K | -227.33%-13.77M | 244.65%10.21M | 751.33%10.81M | -123.66%-7.06M | -62.75%-1.66M | 96.50%-3.16M | -105.81%-1.02M | -206.29%-90.08M | -31.88%17.55M |
Profit attributable to shareholders | 3.54%85.07M | 71.40%55.31M | 340.66%82.16M | 61.62%32.27M | 106.77%18.65M | -50.17%19.97M | 92.59%-275.4M | -37.30%40.08M | -34,085.70%-3.72B | -52.43%63.91M |
Basic earnings per share | 2.78%0.0037 | 71.43%0.0024 | 157.14%0.0036 | -6.67%0.0014 | 106.60%0.0014 | -51.61%0.0015 | 92.59%-0.0212 | -36.73%0.0031 | -35,675.00%-0.2862 | -52.43%0.0049 |
Diluted earnings per share | 2.78%0.0037 | 71.43%0.0024 | 157.14%0.0036 | -6.67%0.0014 | 106.60%0.0014 | -51.61%0.0015 | 92.59%-0.0212 | -36.73%0.0031 | -35,675.00%-0.2862 | 0.0049 |
Currency Unit | CNY | HKD | CNY | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- |
Auditor | -- | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.